The test used for early detection and monitoring of prostate cancer—prostate-specific antigen (PSA)—is one of the most accurate and frequently used tumor markers in medicine today. No tumor marker has had such a critical impact on early detection through stage-migration, and monitoring after treatment for prostate cancer as the blood test PSA. This chapter provides an overview of the PSA test and its distinct molecular forms in blood, in screening, early detection and monitoring of prostate cancer. This chapter gives a summary of the randomized controlled trials of PSA-screening and recommendations from national guidelines groups. The chapter discusses the role of the PSA-test as a tool to discriminate clinically significant from indolent p...
Purpose of review The purpose of this article is to review blood and urine tests that are currently ...
Tumor markers are being used in the early detection of cancer disease, diagnostics, prognosis, thera...
Due to its significant applicability for early detection, risk prediction and follow-up evaluation, ...
Prostate specific antigen (PSA) screening is an integral part of current screening for prostate canc...
In this chapter the use of prostate specific antigen (PSA) as a tumor marker for prostate cancer is ...
Early detection of prostate cancer is problematic, not just because of uncertainly whether a diagnos...
Early detection of prostate cancer is problematic, not just because of uncertainly whether a diagnos...
The limitations of PSA as a screening marker for diagnosis and prostate cancer treatment are well kn...
The discovery of prostate-specific antigen (PSA) as a biomarker represented a major discovery in the...
textabstractSince the first publication describing the identification of prostate-specific antigen (...
Prostate-specific antigen (PSA) screening for prostate cancer is now widespread in the United States...
Despite being used extensively for the diagnosis and management of prostate cancer, prostate-specifi...
Serum prostate markers, in particular prostate-specific antigen (PSA), have truly revolutionised all...
International audienceTo systematically review the evidence for the use of PSA and other biomarkers ...
Since its discovery in 1979, serum PSA has revolutionized how physicians manage men with prostate ca...
Purpose of review The purpose of this article is to review blood and urine tests that are currently ...
Tumor markers are being used in the early detection of cancer disease, diagnostics, prognosis, thera...
Due to its significant applicability for early detection, risk prediction and follow-up evaluation, ...
Prostate specific antigen (PSA) screening is an integral part of current screening for prostate canc...
In this chapter the use of prostate specific antigen (PSA) as a tumor marker for prostate cancer is ...
Early detection of prostate cancer is problematic, not just because of uncertainly whether a diagnos...
Early detection of prostate cancer is problematic, not just because of uncertainly whether a diagnos...
The limitations of PSA as a screening marker for diagnosis and prostate cancer treatment are well kn...
The discovery of prostate-specific antigen (PSA) as a biomarker represented a major discovery in the...
textabstractSince the first publication describing the identification of prostate-specific antigen (...
Prostate-specific antigen (PSA) screening for prostate cancer is now widespread in the United States...
Despite being used extensively for the diagnosis and management of prostate cancer, prostate-specifi...
Serum prostate markers, in particular prostate-specific antigen (PSA), have truly revolutionised all...
International audienceTo systematically review the evidence for the use of PSA and other biomarkers ...
Since its discovery in 1979, serum PSA has revolutionized how physicians manage men with prostate ca...
Purpose of review The purpose of this article is to review blood and urine tests that are currently ...
Tumor markers are being used in the early detection of cancer disease, diagnostics, prognosis, thera...
Due to its significant applicability for early detection, risk prediction and follow-up evaluation, ...